DeepMed Research

University of Minnesota Masonic Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients

Phase 2

Completed

Conditions: Acute Myelogenous Leukemia

Interventions: Biological: IL-15

First Posted Date: 2015-03-24

Last Posted Date: 2018-02-20

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 17

Registration Number: NCT02395822

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma

Phase 1

Completed

Conditions: Refractory B-Lineage Leukemia
Refractory B-Lineage Lymphoma
Relapsed B-Lineage Leukemia
Relapsed B-Lineage Lymphoma

Interventions: Biological: DT2219ARL

First Posted Date: 2015-02-24

Last Posted Date: 2020-01-13

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 18

Registration Number: NCT02370160

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Negative Pressure Wound Therapy in Obese Gynecologic Oncology Patients

Not Applicable

Completed

Conditions: Postoperative Complications
Gynecologic Neoplasms
Obesity

Interventions: Procedure: Standard Wound Closure
Device: Prevena™ Incision Management System

First Posted Date: 2014-12-05

Last Posted Date: 2020-07-27

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 93

Registration Number: NCT02309944

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

MT2013-37R: Voriconazole Monitoring in Pediatric Stem Cell Transplant Patients

Phase 1

Completed

Conditions: Fungal Infection

Interventions: Drug: Voriconazole

First Posted Date: 2014-08-28

Last Posted Date: 2019-04-29

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 66

Registration Number: NCT02227797

Locations: 🇺🇸
University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota, United States

Biomarker Feedback for Smoking Cessation

Not Applicable

Completed

Conditions: Cigarette Smoking

Interventions: Other: urine analyses feedback

First Posted Date: 2014-08-01

Last Posted Date: 2020-01-10

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 109

Registration Number: NCT02206971

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies

Not Applicable

Terminated

Conditions: Paroxysmal Nocturnal Hemoglobinuria
Glanzmann Thrombasthenia
Non-Malignant Hematologic Disorders
Shwachman-Diamond Syndrome
Diamond Blackfan Anemia
Sickle Cell Disease
Transfusion Dependent Alpha- or Beta- Thalassemia
Severe Congenital Neutropenia

Interventions: Drug: Myeloablative Preparative Regimen
Drug: Reduced Toxicity Ablative Regimen
Drug: Reduced Intensity Preparative Regimen

First Posted Date: 2014-07-01

Last Posted Date: 2025-03-03

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 38

Registration Number: NCT02179359

Locations: 🇺🇸
University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota, United States

MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis

Phase 2

Recruiting

Conditions: Maroteaux Lamy Syndrome
Alpha-Mannosidosis
Fucosidosis
Aspartylglucosaminuria
Glycoprotein Metabolic Disorders
Niemann-Pick B
Adrenoleukodystrophy With Cerebral Involvement
Zellweger Syndrome
D-Bifunctional Enzyme Deficiency
Inherited Metabolic Disorders

Interventions: Biological: Stem Cell Transplantation
Drug: IMD Preparative Regimen
Drug: Osteopetrosis Only Preparative Regimen
Drug: Osteopetrosis Haploidentical Only Preparative Regimen
Drug: cALD HR-D (High-Risk, Regimen C)
Drug: cALD SR-B (Standard-Risk, Regimen B)
Drug: cALD SR-A (Standard-Risk, Regimen A)
Drug: cALD HR-D (High-Risk, Regimen D)

First Posted Date: 2014-06-23

Last Posted Date: 2024-11-05

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 100

Registration Number: NCT02171104

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation

Recruiting

Conditions: Secondary Graft Failure
Primary Graft Failure

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: Total Body Irradiation
Biological: Hematopoietic stem cell infusion

First Posted Date: 2014-06-12

Last Posted Date: 2024-12-19

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 50

Registration Number: NCT02161783

Locations: 🇺🇸
University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota, United States

Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia

Not Applicable

Completed

Conditions: Aplastic Anemia
Dyskeratosis Congenita

Interventions: Drug: Alemtuzumab
Drug: Fludarabine
Drug: Cyclophosphamide
Biological: Stem Cell Transplant
Radiation: Total Body Irradiation
Drug: Anti-thymocyte globulin

First Posted Date: 2014-06-12

Last Posted Date: 2025-05-08

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 61

Registration Number: NCT02162420

Locations: 🇺🇸
University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota, United States

Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome

Not Applicable

Terminated

Conditions: Maroteaux-Lamy Syndrome

Interventions: Drug: Naglazyme®

First Posted Date: 2014-06-05

Last Posted Date: 2020-12-23

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 1

Registration Number: NCT02156674

Locations: 🇺🇸
University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy